Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash & Equivalents (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Cash & Equivalents readings, the most recent being $20.5 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 263.8% to $20.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.5 million, a 263.8% increase, with the full-year FY2025 number at $10.5 million, up 18.03% from a year prior.
  • Cash & Equivalents hit $20.5 million in Q1 2026 for SAB Biotherapeutics, up from $10.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $56.6 million in Q4 2023 to a low of $2.4 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $13.1 million (2023), compared with a mean of $15.4 million.
  • The widest YoY moves for Cash & Equivalents: up 279.31% in 2024, down 84.27% in 2024.
  • SAB Biotherapeutics' Cash & Equivalents stood at $15.0 million in 2022, then skyrocketed by 275.93% to $56.6 million in 2023, then plummeted by 84.27% to $8.9 million in 2024, then rose by 18.03% to $10.5 million in 2025, then soared by 95.38% to $20.5 million in 2026.
  • The last three reported values for Cash & Equivalents were $20.5 million (Q1 2026), $10.5 million (Q4 2025), and $29.4 million (Q3 2025) per Business Quant data.